--- title: "Vaxart (VXRT) news: reverse split, delisting and offering" url: "https://aibio.space/companies/vaxart/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "VXRT reverse split, delisting and offering news: Vaxart to be delisted from Nasdaq after missing hearings panel conditions. Vaxart, Inc." --- VXRT Vaxart, Inc. OTC · United States # Vaxart (VXRT) news VXRT reverse split, delisting and offering news Listings · 2025-09-19 ## [Vaxart to be delisted from Nasdaq after missing hearings panel conditions](https://aibio.space/news/vaxart-delisted-nasdaq-after-missing-hearings-panel-conditions/) Nasdaq told Vaxart on September 19, 2025 that its common stock will be delisted after the company withdrew a reverse stock split proposal that a hearings panel had made a condition of continued listing. Trading on Nasdaq was suspended on July 8, 2025. ## Latest Vaxart news 1. 2025-03-21 Financings [Vaxart sets up $50,000,000 at-the-market stock program](https://aibio.space/news/vaxart-sets-up-50-000-000-market-stock-program/) Vaxart agreed on March 21, 2025 to sell up to $50 million of common stock through Citizens JMP Securities and B. Riley Securities, which may each receive a commission of up to 3% of gross sales. The stock closed at $0.5754 on March 17, 2025. ## Vaxart at a glance - **Ticker**: VXRT - **Listing**: OTC - **Country**: United States - **Cash, Jun 30, 2026**: $64.0 million ### Related companies - [ALX Oncology Holdings](https://aibio.space/companies/alx-oncology/) NASDAQ: ALXO - [NANOLOGIX INC](https://aibio.space/companies/nanologix/) OTC: NNLX - [Spruce Biosciences](https://aibio.space/companies/spruce-biosciences/) NASDAQ: SPRB - [Solid Biosciences](https://aibio.space/companies/solid-biosciences/) NASDAQ: SLDB - [Amarantus Bioscience Holdings](https://aibio.space/companies/amarantus-bioscience/) OTC: AMBS - [Zentalis Pharmaceuticals](https://aibio.space/companies/zentalis-pharmaceuticals/) NASDAQ: ZNTL - [Prime Medicine](https://aibio.space/companies/prime-medicine/) NASDAQ: PRME - [Monopar Therapeutics](https://aibio.space/companies/monopar-therapeutics/) NASDAQ: MNPR ### Also on OTC - [PetVivo Holdings](https://aibio.space/companies/petvivo/) PETV - [CBD Life Sciences](https://aibio.space/companies/cbd-life-sciences/) CBDL - [Meihua International Medical Technologies Co.](https://aibio.space/companies/meihua-international-medical-technologies/) MHUAF - [GUIDED THERAPEUTICS INC](https://aibio.space/companies/guided-therapeutics/) GTHP - [MULTICELL TECHNOLOGIES INC](https://aibio.space/companies/multicell-technologies/) MCET - [Yubo International Biotech](https://aibio.space/companies/yubo-international-biotech/) YBGJ ## Vaxart annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$237.3 million](https://www.sec.gov/Archives/edgar/data/72444/000143774926008023/) | [$28.7 million](https://www.sec.gov/Archives/edgar/data/72444/000143774926008023/) | | Research and development | [$201.6 million](https://www.sec.gov/Archives/edgar/data/72444/000143774926008023/) | [$74.2 million](https://www.sec.gov/Archives/edgar/data/72444/000143774926008023/) | | Net income (loss) | [$16.3 million](https://www.sec.gov/Archives/edgar/data/72444/000143774926008023/) | [-$66.9 million](https://www.sec.gov/Archives/edgar/data/72444/000143774926008023/) | | Cash from operations | [$7.7 million](https://www.sec.gov/Archives/edgar/data/72444/000143774926008023/) | [-$44.8 million](https://www.sec.gov/Archives/edgar/data/72444/000143774926008023/) | | Cash and equivalents | [$53.8 million](https://www.sec.gov/Archives/edgar/data/72444/000143774926026289/) | [$25.2 million](https://www.sec.gov/Archives/edgar/data/72444/000143774926008023/) | | Short-term investments | [$10.0 million](https://www.sec.gov/Archives/edgar/data/72444/000143774926026289/) | [$26.5 million](https://www.sec.gov/Archives/edgar/data/72444/000143774926008023/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $50.9 million, plus short-term investments of $13.0 million, $64.0 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Vaxart Did Vaxart do a reverse stock split? Our latest story on this, dated Sep 19, 2025: "Vaxart to be delisted from Nasdaq after missing hearings panel conditions". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/vaxart-delisted-nasdaq-after-missing-hearings-panel-conditions/). Was Vaxart delisted? Our latest story on this, dated Sep 19, 2025: "Vaxart to be delisted from Nasdaq after missing hearings panel conditions". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/vaxart-delisted-nasdaq-after-missing-hearings-panel-conditions/). Has Vaxart raised money recently? Our latest story on this, dated Mar 21, 2025: "Vaxart sets up $50,000,000 at-the-market stock program". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/vaxart-sets-up-50-000-000-market-stock-program/). What is the ticker symbol of Vaxart? Vaxart, Inc. trades under the ticker VXRT on OTC. Where is Vaxart listed? Vaxart, Inc. is listed on OTC. What is the SEC CIK of Vaxart? The SEC Central Index Key (CIK) for Vaxart, Inc. is 72444. Its filings are on SEC EDGAR. How many shares does Vaxart have outstanding? 242,835,358 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Vaxart listed under? Our directory records Vaxart, Inc. under United States. What does Vaxart do? Our directory classifies Vaxart, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Vaxart? The ISIN recorded for Vaxart, Inc. is US92243A2006. Does aibio.space cover Vaxart? aibio.space lists Vaxart, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Vaxart incorporated? SEC records list its state or country of incorporation as DE. What was Vaxart's revenue last year? $237.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Vaxart profitable? Vaxart, Inc. reported net income of $16.3 million for the fiscal year ended Dec 31, 2025, and generated $7.7 million of cash from operations, per its annual report to the SEC. How much does Vaxart spend on research and development? $201.6 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Vaxart Members talk about Vaxart (VXRT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Vaxart, newest first. Each line links the filing it comes from. 1. 2026-05-04 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/72444/000143774926014687/vxrt20260501c_424b5.htm) 2. 2026-04-17 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/72444/000143774926012623/vxrt20260417_8k.htm) 3. 2025-12-29 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/72444/000143774925038774/vxrt20251226_8k.htm) 4. 2025-11-21 Listings Filed to remove its shares from exchange listing. SEC Form 25-NSE. [Source](https://www.sec.gov/Archives/edgar/data/72444/000135445725001171/xslF25X02/primary_doc.xml) 5. 2025-11-05 Financings Reported a financing. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/72444/000143774925033362/vxrt20251104_8k.htm) 6. 2025-09-19 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/72444/000143774925029485/vxrt20250919_8k.htm) 7. 2025-08-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/72444/000143774925028047/vxrt20250829_8k.htm) 8. 2025-08-06 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/72444/000143774925025111/vxrt20250805_def14a.htm) 9. 2025-07-24 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/72444/000143774925023418/vxrt20250717_pre14a.htm) 10. 2025-07-08 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/72444/000143774925022358/vxrt20250708_8k.htm) 11. 2025-07-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/72444/000143774925021865/vxrt20250702_8k.htm) 12. 2025-06-17 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/72444/000143774925020651/vxrt20250613_8k.htm) 13. 2025-06-02 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/72444/000143774925019181/vxrt20250602_8k.htm) 14. 2025-05-29 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/72444/000143774925018703/vxrt20250526_pre14a.htm) 15. 2025-05-28 Listings Reported a reverse stock split. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/72444/000143774925018648/vxrt20250528_8k.htm) 16. 2025-05-16 Listings Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/72444/000143774925017302/vxrt20250515c_8k.htm) 17. 2025-05-12 Listings Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/72444/000143774925015960/vxrt20250511_8k.htm) 18. 2025-05-05 Listings Reported a reverse stock split. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/72444/000143774925014405/vxrt20250503_8k.htm) 19. 2025-04-10 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/72444/000143774925011669/vxrt20250402_def14a.htm) 20. 2025-03-31 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/72444/000143774925010263/vxrt20250330_pre14a.htm) 21. 2025-03-21 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/72444/000143774925008756/vxrt20250321_424b5.htm) 22. 2025-03-20 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/72444/000143774925008572/vxrt20241231_10k.htm) 23. 2024-12-31 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/72444/000143774924038599/vxrt20241231_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:VXRT on TradingView](https://www.tradingview.com/symbols/OTC-VXRT/). ## SEC filings and registration - **SEC name**: Vaxart, Inc. - **CIK**: 72444 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: VXRT (OTC) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Accelerated filer
Smaller reporting company - **Business address**: 310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA - **Phone**: (650) 550-3500 - **Shares outstanding**: 242,835,358 as of 2026-07-31 (10-Q filed 2026-08-06) - **Former names**: Aviragen Therapeutics, Inc.; Biota Pharmaceuticals, Inc.; NABI BIOPHARMACEUTICALS ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/72444/000143774926032932/vxrt20261016_8k.htm) filed 2026-10-19 - [8-K](https://www.sec.gov/Archives/edgar/data/72444/000143774926030318/vxrt20260914_8k.htm) filed 2026-09-14 - [8-K](https://www.sec.gov/Archives/edgar/data/72444/000143774926028916/vxrt20260824_8k.htm) filed 2026-08-25 - [10-Q](https://www.sec.gov/Archives/edgar/data/72444/000143774926026289/vxrt20260630_10q.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/72444/000143774926026280/vxrt20260806_8k.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/72444/000143774926024560/vxrt20260727_8k.htm) filed 2026-07-28 - [8-K](https://www.sec.gov/Archives/edgar/data/72444/000143774926023762/vxrt20260717_8k.htm) filed 2026-07-17 - [8-K](https://www.sec.gov/Archives/edgar/data/72444/000143774926022876/vxrt20260706_8k.htm) filed 2026-07-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000072444), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Vaxart, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker VXRT, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Vaxart, Inc. - **Ticker**: VXRT - **Listing**: OTC - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US92243A2006 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-VXRT/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/vaxart/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Vaxart (VXRT) news: reverse split, delisting and offering", 2026-10-31, https://aibio.space/companies/vaxart/